Literature DB >> 9413097

The outer surface protein A (OspA) vaccine against Lyme disease: efficacy in the rhesus monkey.

M T Philipp1, Y Lobet, R P Bohm, E D Roberts, V A Dennis, Y Gu, R C Lowrie, P Desmons, P H Duray, J D England, P Hauser, J Piesman, K Xu.   

Abstract

The efficacy of an outer surface protein A (OspA) vaccine in three different formulations was investigated in the rhesus monkey. The challenge infection was administered using Ixodes scapularis ticks that were infected with the B31 strain of Borrelia burgdorferi. Protection was assessed against both infection and disease, by a variety of procedures. Some of the animals were radically immune suppressed, as an attempt to reveal any putative low level infection in the vaccinated animals. The significant difference found between the spirochaetal infection rates of ticks that had fed on vaccinated vs. control monkeys, lack of seroconversion in the vaccinated animals, and the absence of spirochaetal DNA in the skin of vaccinated animals in the weeks following the challenge, indicate that vaccinated monkeys were protected against tick challenge. The post-mortem immunohistochemical and polymerase chain reaction analyses, however, suggest that these monkeys may have undergone a low-level infection that was transient.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9413097     DOI: 10.1016/s0264-410x(97)00133-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

Review 1.  Critical analysis of treatment trials of rhesus macaques infected with Borrelia burgdorferi reveals important flaws in experimental design.

Authors:  Gary P Wormser; Phillip J Baker; Susan O'Connell; Andrew R Pachner; Ira Schwartz; Eugene D Shapiro
Journal:  Vector Borne Zoonotic Dis       Date:  2012-05-23       Impact factor: 2.133

2.  Feeding of ticks on animals for transmission and xenodiagnosis in Lyme disease research.

Authors:  Monica E Embers; Britton J Grasperge; Mary B Jacobs; Mario T Philipp
Journal:  J Vis Exp       Date:  2013-08-31       Impact factor: 1.355

3.  Cloning and molecular characterization of plasmid-encoded antigens of Borrelia burgdorferi.

Authors:  J T Skare; D M Foley; S R Hernandez; D C Moore; D R Blanco; J N Miller; M A Lovett
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

4.  Killing of Borrelia burgdorferi by antibody elicited by OspA vaccine is inefficient in the absence of complement.

Authors:  J M Nowling; M T Philipp
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

5.  Lyme borreliosis in rhesus macaques: effects of corticosteroids on spirochetal load and isotype switching of anti-borrelia burgdorferi antibody.

Authors:  A R Pachner; K Amemiya; M Bartlett; H Schaefer; K Reddy; W F Zhang
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

6.  Cryptic and exposed invariable regions of VlsE, the variable surface antigen of Borrelia burgdorferi sl.

Authors:  F T Liang; J M Nowling; M T Philipp
Journal:  J Bacteriol       Date:  2000-06       Impact factor: 3.490

7.  Borrelia burgdorferi escape mutants that survive in the presence of antiserum to the OspA vaccine are killed when complement is also present.

Authors:  M Solé; C Bantar; K Indest; Y Gu; R Ramamoorthy; R Coughlin; M T Philipp
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

8.  Adjuvanted Lyme disease vaccine: a review of its use in the management of Lyme disease.

Authors:  S V Onrust; K L Goa
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

9.  Detection of immune complexes is not independent of detection of antibodies in Lyme disease patients and does not confirm active infection with Borrelia burgdorferi.

Authors:  Adriana R Marques; Ronald L Hornung; Len Dally; Mario T Philipp
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

10.  Analysis of antibody response to invariable regions of VlsE, the variable surface antigen of Borrelia burgdorferi.

Authors:  F T Liang; M T Philipp
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.